KR20180070708A - 상처 치유를 위한 플라스미노겐 투여 요법 - Google Patents

상처 치유를 위한 플라스미노겐 투여 요법 Download PDF

Info

Publication number
KR20180070708A
KR20180070708A KR1020187016082A KR20187016082A KR20180070708A KR 20180070708 A KR20180070708 A KR 20180070708A KR 1020187016082 A KR1020187016082 A KR 1020187016082A KR 20187016082 A KR20187016082 A KR 20187016082A KR 20180070708 A KR20180070708 A KR 20180070708A
Authority
KR
South Korea
Prior art keywords
wound
plasminogen
biologically active
dose
active variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187016082A
Other languages
English (en)
Korean (ko)
Inventor
울프 베르타임
토르 니
피에르 로렝
마틴 로비테일
Original Assignee
프로메틱 바이오테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메틱 바이오테라퓨틱스 리미티드 filed Critical 프로메틱 바이오테라퓨틱스 리미티드
Publication of KR20180070708A publication Critical patent/KR20180070708A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020187016082A 2015-11-10 2016-11-10 상처 치유를 위한 플라스미노겐 투여 요법 Withdrawn KR20180070708A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562253352P 2015-11-10 2015-11-10
US62/253,352 2015-11-10
PCT/IB2016/001606 WO2017081529A1 (en) 2015-11-10 2016-11-10 Plasminogen dosage regimen for wound healing

Publications (1)

Publication Number Publication Date
KR20180070708A true KR20180070708A (ko) 2018-06-26

Family

ID=57485826

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016082A Withdrawn KR20180070708A (ko) 2015-11-10 2016-11-10 상처 치유를 위한 플라스미노겐 투여 요법

Country Status (14)

Country Link
US (1) US20180326023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3373957A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018534306A (cg-RX-API-DMAC7.html)
KR (1) KR20180070708A (cg-RX-API-DMAC7.html)
CN (1) CN108289934A (cg-RX-API-DMAC7.html)
AU (1) AU2016352183A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018009476A8 (cg-RX-API-DMAC7.html)
CA (1) CA3004509A1 (cg-RX-API-DMAC7.html)
IL (1) IL259172A (cg-RX-API-DMAC7.html)
MX (1) MX2018005876A (cg-RX-API-DMAC7.html)
RU (1) RU2018121234A (cg-RX-API-DMAC7.html)
TW (1) TW201722464A (cg-RX-API-DMAC7.html)
WO (1) WO2017081529A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201803010B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN111432762B (zh) * 2017-12-15 2023-01-13 墨尼克医疗用品有限公司 预防性敷料
BR112020003022A2 (pt) 2017-12-26 2020-08-25 Hirotaro Fukuoka composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo
JP7682567B2 (ja) * 2020-11-17 2025-05-26 泰▲倫▼基国▲際▼有限公司 Ngfレベルを増加させる方法及び薬剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
EP2249863A4 (en) * 2008-01-22 2011-12-28 Omnio Healer Ab METHOD OF ENHANCING WOUND HEALING
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法

Also Published As

Publication number Publication date
WO2017081529A1 (en) 2017-05-18
MX2018005876A (es) 2018-11-09
EP3373957A1 (en) 2018-09-19
RU2018121234A3 (cg-RX-API-DMAC7.html) 2020-03-12
AU2016352183A1 (en) 2018-06-28
TW201722464A (zh) 2017-07-01
CN108289934A (zh) 2018-07-17
US20180326023A1 (en) 2018-11-15
ZA201803010B (en) 2019-07-31
IL259172A (en) 2018-06-28
JP2018534306A (ja) 2018-11-22
BR112018009476A8 (pt) 2019-02-26
RU2018121234A (ru) 2019-12-13
CA3004509A1 (en) 2017-05-18
BR112018009476A2 (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
KR101534468B1 (ko) 당뇨병성 궤양 치료를 위한 약제제조를 위한 약학 조성물의 용도
US9962402B2 (en) Healing composition for topical application
KR100795654B1 (ko) 당뇨성 발 절단 예방을 위한 표피성장인자 함유 약제학적조성물의 용도
Ranjbar Overview of diabetic foot; novel treatments in diabetic foot ulcer
Crotty et al. Ulcerative lichen planus: follow-up of surgical excision and grafting
US20180326023A1 (en) Plasminogen dosage regimen for wound healing
Liu et al. Experimental study on the effect of chrysin on skin injury induced by amiodarone extravasation in rats
US7374772B2 (en) Topical antifungal treatment
RU2734159C1 (ru) Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием
KR102158969B1 (ko) 물질 p를 포함하는 난치성 궤양 치료용 조성물
US10960011B2 (en) Compositions for the treatment of ischemic ulcers and stretch marks
US20230181661A1 (en) Mushroom-containing chinese medicine compound composition for keloid scar tissue and application thereof
US12521392B2 (en) Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias
TW201632191A (zh) 一種用於促進傷口癒合或預防、減少傷口疤痕生成的醫藥組合物
RU2539385C2 (ru) Способ лечения синдрома диабетической стопы
CN108635362A (zh) 一种治疗糖尿病足的药物组合物
Wynn et al. Case Report: Wound Care of a Diabetic Foot Ulcer.
Alam et al. Non-healing Ulcer Treated with Unani Formulation Zaroor-e-Qaw: A Case Report
Gayathridevi et al. Effectiveness of Siddha Formulation Chitramoola Kuligai (CMK Tablet) In Treatment of Viranangal (Ulcers)–A Case Study of Two
BISWAS MANAGEMENT OF SNAKE BITE
Rosenberg A New Method for Treating Slow-healing Wounds
KR20230136597A (ko) 상처 치료를 위한 조성물들 및 방법들
Garcia et al. The beneficial effect of motorised ankle dorsiflexion on the healing of diabetic foot ulcers
Pennock et al. Vitamin E in treatment of leg ulcers
REKHA A COMPARATIVE STUDY OF COLLAGEN

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180607

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid